Manufacturing & Packaging

The acquisition of the 87,000 square-foot Camden, MD plant provides the CDMO with the ability to offer clinical and commercial non-viral aseptic fill-finish services on four fill lines.

The contract manufacturer financially committed over $107 million into the facility, which can reportedly handle large-scale manufacturing of active ingredients based on messenger ribonucleic acid.

The 53,000 square-foot facility is expected to become a Northeastern biotech hub, and will be home to various CGT services.

The $530 million investment will accelerate the company’s development and production process for therapies in the rare disease space.

New innovations that are contributing to industry environmental efforts.

The development and manufacturing plant will be constructed in Texas, and is expected to become operational by Q1 2025.

The new plant in Italy is expected to tackle the rise in biopharmaceutical material demand, specifically for GLP-1s.

The Netherlands plant is expected to provide solutions that can help further the development of advanced therapies.

Financial commitment will go toward expanding the CDMO’s integrated antibody-drug conjugate services.

With the acquisition, Merck’s US and Canada life science business aims to further increase its viral vector manufacturing capabilities.

The CDMO will run the active pharmaceutical ingredient pilot plant in Sandwich, UK, along with development laboratories.

The agreement is expected to focus on cell manufacturing processes, with potential for sharing tech with academia, startups.

The facility, company says, will be its first that covers end-to-end ADC production.

The CDMO’s latest business venture reaffirms its commitment to the development of novel radiopharmaceuticals.

The company has financially committed more than $3.8 billion since the COVID-19 pandemic into keeping the medication and vaccine production process in France.

The development project adds an additional 157,500 square feet to the existing facility in the process.

The CDMO’s Bedford, NH facility will welcome a new isolator filling line—along with twin lyophilizers—as part of a multi-year, $100 million capital investment project.

The CDMO’s boost in production will be centered around pharmaceutical products.

The company adds a top-10 CDMO to its portfolio in the process, while also expanding its commitment to the pharma industry.

The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.

The acquisition initiates a long-term agreement with Beacon Therapeutics, highlighted by clinical and commercial AAV production.

The purpose for the deal, the CDMO says, is to meet the demand for commercial mammalian contract manufacturing.

A proposed Senate bill is intended to protect citizens’ private health and genetic information.

The CDMO’s multi-million-dollar expansion project features commercial manufacturing suites and peptide manufacturing plants.

The purchase boosts the parties’ sterile liquid manufacturing capabilities.